FENNEC PHARMACEUTICALS INC. (FENC)
Every FINRA and SEC series the site collects for FENNEC PHARMACEUTICALS INC.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
532K
Short interest
settlement 2026-08-14
2.2
Days to cover
-13.6% vs prior
39.7%
Short share of volume
2026-09-11
557
Fails to deliver
settlement 2026-08-12
-$1.2M
Insider flow, 90 days
0 buys, 4 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 14 August 2026, short interest in FENC is 532,095 shares, down 77,094 shares over the last month. Over the last 48 readings it ranged from 450,578 shares (15 June 2026) to 2,108,899 shares (13 December 2024). The latest reading sits at the bottom of that range. At the reported average volume of 245K shares a day that is 2.2 days to cover.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/fenc" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 532,095 | -13.6% | 245,478 | 2.17 |
| 2026-07-31 | 615,869 | +1.1% | 115,860 | 5.32 |
| 2026-07-15 | 609,189 | +24.6% | 182,924 | 3.33 |
| 2026-06-30 | 488,731 | +8.5% | 366,003 | 1.34 |
| 2026-06-15 | 450,578 | -9.5% | 224,711 | 2.01 |
| 2026-05-29 | 498,119 | -20.1% | 355,955 | 1.40 |
| 2026-05-15 | 623,377 | -41.2% | 386,241 | 1.61 |
| 2026-04-30 | 1,060,249 | +13.9% | 118,179 | 8.97 |
| 2026-04-15 | 930,606 | +1.9% | 177,094 | 5.25 |
| 2026-03-31 | 913,271 | +13.2% | 308,600 | 2.96 |
| 2026-03-13 | 806,566 | -2.1% | 126,101 | 6.40 |
| 2026-02-27 | 824,295 | +1.6% | 115,644 | 7.13 |
| 2026-02-13 | 811,612 | +5.5% | 105,700 | 7.68 |
| 2026-01-30 | 769,534 | +3.8% | 94,459 | 8.15 |
| 2026-01-15 | 741,610 | -4.7% | 134,293 | 5.52 |
| 2025-12-31 | 777,869 | -9.5% | 212,304 | 3.66 |
| 2025-12-15 | 859,138 | -2.6% | 149,751 | 5.74 |
| 2025-11-28 | 882,225 | -17.8% | 219,145 | 4.03 |
| 2025-11-14 | 1,073,787 | +9.5% | 147,488 | 7.28 |
| 2025-10-31 | 980,887 | -25.0% | 71,887 | 13.64 |
| 2025-10-15 | 1,308,525 | +0.3% | 73,959 | 17.69 |
| 2025-09-30 | 1,303,927 | -1.8% | 112,112 | 11.63 |
| 2025-09-15 | 1,327,328 | +6.5% | 47,917 | 27.70 |
| 2025-08-29 | 1,246,841 | -2.6% | 63,336 | 19.69 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of FENC volume is 39.7%, up 16.0 points over the last five sessions. Over the last 52 readings it ranged from 15.6% (21 August 2026) to 66.0% (27 July 2026). The latest reading is 8.6 points above the 30-session average of 31.1%, on 96K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 38K | 96K | 39.7% | 0 |
| 2026-09-10 | 29K | 67K | 43.6% | 0 |
| 2026-09-09 | 56K | 150K | 37.4% | 5,423 |
| 2026-09-08 | 52K | 140K | 37.3% | 8,334 |
| 2026-09-04 | 27K | 104K | 26.1% | 391 |
| 2026-09-03 | 34K | 142K | 23.7% | 0 |
| 2026-09-02 | 23K | 136K | 16.9% | 0 |
| 2026-09-01 | 32K | 193K | 16.4% | 0 |
| 2026-08-31 | 62K | 273K | 22.6% | 0 |
| 2026-08-28 | 49K | 251K | 19.6% | 0 |
| 2026-08-27 | 23K | 134K | 17.1% | 0 |
| 2026-08-26 | 44K | 124K | 35.5% | 703 |
| 2026-08-25 | 22K | 94K | 23.0% | 0 |
| 2026-08-24 | 34K | 114K | 29.9% | 10,478 |
| 2026-08-21 | 14K | 89K | 15.6% | 1,200 |
| 2026-08-20 | 21K | 110K | 19.4% | 0 |
| 2026-08-19 | 13K | 68K | 18.9% | 10 |
| 2026-08-18 | 14K | 43K | 31.8% | 1,700 |
| 2026-08-17 | 29K | 84K | 34.6% | 0 |
| 2026-08-14 | 16K | 45K | 34.7% | 0 |
| 2026-08-13 | 23K | 90K | 25.4% | 0 |
| 2026-08-12 | 40K | 152K | 26.3% | 0 |
| 2026-08-11 | 93K | 361K | 25.8% | 5,900 |
| 2026-08-10 | 34K | 101K | 33.3% | 0 |
| 2026-08-07 | 50K | 107K | 46.2% | 0 |
| 2026-08-06 | 19K | 46K | 41.0% | 0 |
| 2026-08-05 | 35K | 59K | 60.2% | 0 |
| 2026-08-04 | 23K | 53K | 43.2% | 0 |
| 2026-08-03 | 9K | 30K | 29.7% | 0 |
| 2026-07-31 | 15K | 25K | 58.7% | 0 |
Fails to deliver
SEC, by settlement date. JSONAs of 12 August 2026, the fails-to-deliver balance in FENC is 557 shares, down 2,227 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (24 February 2026) to 70,395 shares (22 September 2025). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-12 | 557 | $12.78 | $7K |
| 2026-08-07 | 2,784 | $10.84 | $30K |
| 2026-07-28 | 671 | $10.21 | $7K |
| 2026-07-20 | 8,526 | $10.50 | $90K |
| 2026-07-14 | 6 | $10.75 | $65 |
| 2026-06-29 | 4,122 | $11.02 | $45K |
| 2026-06-24 | 4,352 | $10.30 | $45K |
| 2026-06-11 | 16 | $8.70 | $139 |
| 2026-06-08 | 2 | $8.70 | $17 |
| 2026-06-03 | 6,913 | $9.98 | $69K |
| 2026-04-10 | 517 | $6.40 | $3K |
| 2026-04-08 | 304 | $6.32 | $2K |
| 2026-04-07 | 1,118 | $6.42 | $7K |
| 2026-03-31 | 100 | $5.77 | $577 |
| 2026-03-23 | 5 | $7.32 | $37 |
| 2026-02-25 | 55,580 | $8.91 | $495K |
| 2026-02-24 | 1 | $8.99 | $9 |
| 2026-02-19 | 32,085 | $8.97 | $288K |
| 2026-02-18 | 246 | $8.68 | $2K |
| 2026-01-20 | 32 | $7.59 | $243 |
| 2026-01-16 | 32 | $7.46 | $239 |
| 2026-01-05 | 701 | $7.68 | $5K |
| 2025-12-19 | 740 | $7.58 | $6K |
| 2025-12-17 | 7,999 | $7.62 | $61K |
| 2025-12-12 | 13 | $7.49 | $97 |
| 2025-12-04 | 1,437 | $7.57 | $11K |
| 2025-11-25 | 1,250 | $7.72 | $10K |
| 2025-11-06 | 1,453 | $8.25 | $12K |
| 2025-10-27 | 4,198 | $8.99 | $38K |
| 2025-10-24 | 4,256 | $8.96 | $38K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONInsiders at FENC reported 4 open-market sells worth $1.2M in the last 90 days and no open-market buys. Sells alone are a weak signal; insiders sell for tax, diversification and estate reasons all the time. Latest filing: Raykov Rosty on 2026-09-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | Raykov Rosty | n/a | Sell | 10K | $12.11 | $121K | 124K |
| 2026-08-31 | Raykov Rosty | n/a | Grant | 3K | $0.00 | $0 | 134K |
| 2026-08-31 | Sayad Pierre Sargis | Chief Medical Officer | Sell | 12K | $12.18 | $146K | 10K |
| 2026-08-31 | Sayad Pierre Sargis | Chief Medical Officer | Grant | 168 | $0.00 | $0 | 22K |
| 2026-08-31 | Hackman Jeffrey S. | Chief Executive Officer | Grant | 1K | $0.00 | $0 | 66K |
| 2026-08-31 | Evans Terry L | Chief Commercial Officer | Grant | 168 | $0.00 | $0 | 22K |
| 2026-08-31 | Cioffi Christiana Marie | Chief Strategy Officer | Grant | 156 | $0.00 | $0 | 25K |
| 2026-08-31 | Andrade Robert | CHIEF FINANCIAL OFFICER | Grant | 2K | $0.00 | $0 | 241K |
| 2026-08-28 | Andrade Robert | CHIEF FINANCIAL OFFICER | Option exercise | 22K | $5.10 | $112K | 240K |
| 2026-08-27 | Andrade Robert | CHIEF FINANCIAL OFFICER | Sell | 75K | $11.78 | $884K | 218K |
| 2026-08-03 | Raykov Rosty | n/a | Sell | 10K | $9.58 | $96K | 132K |
| 2026-07-31 | Sayad Pierre Sargis | Chief Medical Officer | Grant | 168 | $0.00 | $0 | 21K |
| 2026-07-31 | Hackman Jeffrey S. | Chief Executive Officer | Grant | 1K | $0.00 | $0 | 65K |
| 2026-07-31 | Raykov Rosty | n/a | Grant | 3K | $0.00 | $0 | 142K |
| 2026-07-31 | Evans Terry L | Chief Commercial Officer | Grant | 168 | $0.00 | $0 | 21K |
| 2026-07-31 | Cioffi Christiana Marie | Chief Strategy Officer | Grant | 156 | $0.00 | $0 | 24K |
| 2026-07-31 | Andrade Robert | CHIEF FINANCIAL OFFICER | Grant | 2K | $0.00 | $0 | 293K |
| 2026-06-30 | Andrade Robert | CHIEF FINANCIAL OFFICER | Grant | 2K | $0.00 | $0 | 291K |
| 2026-06-01 | Raykov Rosty | n/a | Sell | 10K | $9.62 | $94K | 130K |
| 2026-06-01 | Raykov Rosty | n/a | Option exercise | 16K | $2.45 | $38K | 140K |
| 2026-05-31 | Sayad Pierre Sargis | Chief Medical Officer | Grant | 168 | $0.00 | $0 | 21K |
| 2026-05-31 | Hackman Jeffrey S. | Chief Executive Officer | Grant | 1K | $0.00 | $0 | 63K |
| 2026-05-31 | Evans Terry L | Chief Commercial Officer | Grant | 168 | $0.00 | $0 | 21K |
| 2026-05-31 | Cioffi Christiana Marie | Chief Strategy Officer | Grant | 156 | $0.00 | $0 | 24K |
| 2026-05-31 | Andrade Robert | CHIEF FINANCIAL OFFICER | Grant | 2K | $0.00 | $0 | 289K |
| 2026-05-31 | Raykov Rosty | n/a | Grant | 3K | $0.00 | $0 | 124K |
| 2026-05-11 | RALLIS CHRIS A | n/a | Sell | 8K | $7.04 | $59K | 63K |
| 2026-05-11 | RALLIS CHRIS A | n/a | Option exercise | 14K | $2.44 | $35K | 71K |
| 2026-05-01 | Raykov Rosty | n/a | Sell | 11K | $6.47 | $70K | 121K |
| 2026-05-01 | Raykov Rosty | n/a | Option exercise | 16K | $2.45 | $38K | 132K |
| 2026-04-30 | Sayad Pierre Sargis | Chief Medical Officer | Option exercise | 168 | $0.00 | $0 | 21K |
| 2026-04-30 | Hackman Jeffrey S. | Chief Executive Officer | Option exercise | 1K | $0.00 | $0 | 62K |
| 2026-04-30 | Raykov Rosty | n/a | Option exercise | 3K | $0.00 | $0 | 117K |
| 2026-04-30 | Evans Terry L | Chief Commercial Officer | Option exercise | 168 | $0.00 | $0 | 21K |
| 2026-04-30 | Cioffi Christiana Marie | Chief Strategy Officer | Option exercise | 155 | $0.00 | $0 | 24K |
| 2026-04-30 | Andrade Robert | CHIEF FINANCIAL OFFICER | Option exercise | 2K | $0.00 | $0 | 288K |
| 2026-04-01 | Raykov Rosty | n/a | Sell | 11K | $6.31 | $69K | 114K |
| 2026-04-01 | Raykov Rosty | n/a | Option exercise | 16K | $2.45 | $38K | 125K |
| 2026-03-31 | Sayad Pierre Sargis | Chief Medical Officer | Option exercise | 171 | $0.00 | $0 | 19K |
| 2026-03-31 | Sayad Pierre Sargis | Chief Medical Officer | Option exercise | 18K | $0.00 | $0 | 18K |
| 2026-03-31 | Hackman Jeffrey S. | Chief Executive Officer | Option exercise | 1K | $0.00 | $0 | 47K |
| 2026-03-31 | Hackman Jeffrey S. | Chief Executive Officer | Option exercise | 17K | $0.00 | $0 | 45K |
| 2026-03-31 | Raykov Rosty | n/a | Grant | 5K | $0.00 | $0 | 109K |
| 2026-03-31 | Evans Terry L | Chief Commercial Officer | Option exercise | 171 | $0.00 | $0 | 19K |
| 2026-03-31 | Evans Terry L | Chief Commercial Officer | Option exercise | 18K | $0.00 | $0 | 18K |
| 2026-03-31 | Cioffi Christiana Marie | Chief Strategy Officer | Option exercise | 158 | $0.00 | $0 | 22K |
| 2026-03-31 | Cioffi Christiana Marie | Chief Strategy Officer | Option exercise | 17K | $0.00 | $0 | 22K |
| 2026-03-31 | Andrade Robert | CHIEF FINANCIAL OFFICER | Option exercise | 2K | $0.00 | $0 | 274K |
| 2026-03-31 | Andrade Robert | CHIEF FINANCIAL OFFICER | Option exercise | 15K | $0.00 | $0 | 271K |
| 2026-03-28 | Sayad Pierre Sargis | Chief Medical Officer | Option exercise | 2K | $0.00 | $0 | 21K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Planned sales (Form 144)
Newest first. JSON4 Form 144 notices on file for FENC worth $1.2M at the prices reported; 4 in the last 90 days worth $1.2M. Latest: ROSTISLAV RAYKOV filed on 2026-09-01 to sell 10,000 shares ($121K) from 2026-09-01.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-09-01 | ROSTISLAV RAYKOVFormer Director | 10K | $121K | 0.029% | 2026-09-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-31 | PIERRE S SAYADOfficer | 12K | $146K | 0.034% | 2026-08-31 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-27 | ROBERT ANDRADEOfficer | 75K | $884K | 0.214% | 2026-08-27 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-08-03 | ROSTISLAV RAYKOVFormer Director | 10K | $96K | 0.029% | 2026-08-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person, newest filing first. JSON12 holders above 5% have filed on FENC, all on Schedule 13G (passive). The largest reported stake is Rosalind Advisors, Inc. at 9.6% of the class (3,321,333 shares), filed 2026-08-13 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 4 | Solas Capital Management, LLCinvestment adviser, parent holding company, other entity | 1.9M | 5.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 4 | FREDERICK TUCKER GOLDENparent holding company, individual | 1.9M | 5.4% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Southpoint Capital Advisors LLCother entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Southpoint Capital Advisors LPpartnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Southpoint GP, LPpartnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Southpoint GP, LLCother entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | John S. Clark IIindividual | 0 | 0.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 3 | Southpoint Master Fund, LPpartnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 3 | Rosalind Advisors, Inc.corporation | 3.3M | 9.6% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 3 | SALAMON STEVEN A Jindividual | 3.3M | 9.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 3 | Aharon Gilindividual | 3.2M | 9.4% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 3 | Rosalind Master Fund L.P.partnership | 3.2M | 9.2% | 2026-06-30 |
13F holders
Tracked managers holding FENC at their latest 13F. JSON6 of the 30 tracked managers held FENC at their latest 13F, $4.7M in total at quarter-end prices. Renaissance Technologies is the largest at $1.4M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 134K | $1.4M | 0.00% | +114K |
| AQR Capital Management | 2026-06-30 | 93K | $999K | 0.00% | +69K |
| Citadel Advisors | 2026-06-30 | 71K | $764K | 0.00% | -83K |
| Two Sigma Investments | 2026-06-30 | 60K | $649K | 0.00% | +47K |
| Point72 Asset Management | 2026-06-30 | 56K | $606K | 0.00% | +35K |
| Millennium Management | 2026-06-30 | 26K | $283K | 0.00% | +10K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 2026 (quarter ended 2026-06-30) FENNEC PHARMACEUTICALS INC. reported revenue of $17.9M, up 85.2% from the same quarter a year earlier, and net income of $2.0M (0.05 diluted EPS). In FY 2025 it generated -$12.5M of operating cash flow.
- Cash
- $41.2M
- Equity
- $42.4M
- Total assets
- $75.8M
- Shares outstanding
- 35,067,159
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $17.9M | $2.0M | 11.0% | 0.05 |
| Q1 2026 | 2026-03-31 | $15.1M | $201K | 1.3% | 0.01 |
| Q4 2025derived | 2025-12-31 | $13.8M | n/a | n/a | n/a |
| Q3 2025 | 2025-09-30 | $12.5M | -$638K | -5.1% | -0.02 |
| Q2 2025 | 2025-06-30 | $9.7M | -$3.2M | -32.7% | -0.11 |
| Q1 2025 | 2025-03-31 | $8.8M | -$1.2M | -13.3% | -0.04 |
| Q4 2024derived | 2024-12-31 | $7.9M | n/a | n/a | n/a |
| Q3 2024 | 2024-09-30 | $7.0M | -$5.7M | -82.2% | -0.21 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $44.6M | n/a | -$12.5M | n/a | n/a | n/a |
| FY 2024 | 2024-12-31 | $47.5M | n/a | $27.0M | n/a | n/a | n/a |
| FY 2023 | 2023-12-31 | $21.3M | n/a | -$17.1M | n/a | n/a | n/a |
| FY 2022 | 2022-12-31 | $1.5M | -$23.7M | -$18.1M | n/a | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | -$17.3M | -$14.2M | n/a | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-11 from the cover page.
What this page is
FENNEC PHARMACEUTICALS INC. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows FENNEC PHARMACEUTICALS INC. (FENC), SEC CIK 1211583, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-12.JSON and CSV
- Planned sales
- SEC EDGAR Form 144EDGAR read every 30 minutes; a notice is filed on or before the sell order. Latest 2026-09-01.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GEDGAR read every 30 minutes; 13D within five business days of crossing 5%, 13G on the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-09-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 1211583Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 09:50 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
- KYMRKymera Therapeutics, Inc.
- ADPTAdaptive Biotechnologies Corp
- TWSTTwist Bioscience Corp
- HALOHALOZYME THERAPEUTICS, INC.
- KRYSKrystal Biotech, Inc.
- NBIXNEUROCRINE BIOSCIENCES INC
- RVMDRevolution Medicines, Inc.
- AMGNAMGEN INC
- MAZEMaze Therapeutics, Inc.
- GILDGILEAD SCIENCES, INC.
- RXRXRECURSION PHARMACEUTICALS, INC.
- APGEApogee Therapeutics, Inc.
- PCVXVaxcyte, Inc.
- BIIBBIOGEN INC.
- VORVor Biopharma Inc.
- EXELEXELIXIS, INC.
- SRRKScholar Rock Holding Corp
- ADMAADMA BIOLOGICS, INC.
- VCELVericel Corp
- TECHBIO-TECHNE Corp
- ARTVArtiva Biotherapeutics, Inc.
- BCRXBIOCRYST PHARMACEUTICALS INC
- VIRVir Biotechnology, Inc.
- IOVAIOVANCE BIOTHERAPEUTICS, INC.
Datasets
Frequently Asked Questions
How much of FENC is sold short?
What is FENC's daily short volume?
Does FENC have fails to deliver?
Are FENC insiders buying or selling?
Have FENC insiders filed to sell?
Who owns more than 5% of FENC?
What did FENC report last quarter?
Which funds hold FENC?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.